$CWBR

CohBar Inc

  • NASDAQ
  • Health Technology
  • Biotechnology

PRICE

$0.1755 ▲0.228%

Extented Hours

VOLUME

119,559

DAY RANGE

0.174 - 0.1849

52 WEEK

0.17 - 1.35

Join Discuss about CWBR with like-minded investors

profile
@Math #StockTraders.NET
recently

$FULC and $CWBR were the ones

80 Replies 8 👍 10 🔥

profile
@Math #StockTraders.NET
recently

$CWBR should have been your focus imo

68 Replies 9 👍 11 🔥

profile
@Math #StockTraders.NET
recently

$CWBR eat $heit apes

124 Replies 13 👍 15 🔥

profile
@Math #StockTraders.NET
recently

$CWBR cancer action

136 Replies 9 👍 15 🔥

profile
@maletone #StockTraders.NET
recently

watching $CWBR

77 Replies 10 👍 8 🔥

profile
@achatzi #ivtrades
recently

Good Morning all. $ADRX, $CWBR, $AXSM

92 Replies 13 👍 15 🔥

Key Metrics

Market Cap

15.47 M

Beta

0.98

Avg. Volume

257.27 K

Shares Outstanding

87.15 M

Yield

0%

Public Float

0

Next Earnings Date

2022-11-14

Next Dividend Date

Company Information

CohBar is a clinical stage biotechnology company focused on the research and development of mitochondria based therapeutics, an emerging class of drugs for the treatment of chronic and age-related diseases. Mitochondria based therapeutics originate from the discovery by CohBar's founders of a novel group of naturally occurring peptide sequences within the mitochondrial genome, some of which have been shown to have the potential to regulate key processes in multiple systems and organs in the body. To date, the company has discovered more than 100 mitochondrial derived peptides and generated over 1,000 analogs. CohBar's efforts focus on the development of these peptides into therapeutics that offer the potential to address a broad range of diseases because of the underlying impact of mitochondrial dysfunction. The company's lead compound, CB4211, is in the Phase 1b stage of a Phase 1a/1b clinical trial for NASH and obesity. In addition, CohBar has 4 preclinical programs: CB5138 Analogs for fibrotic diseases, CB5064 Analogs for COVID-19 associated ARDS, MBT5 Analogs for CXCR4-related cancer and orphan diseases, and MBT3 Analogs for cancer immunotherapy.

Website:

HQ: ,

Related News